Digostics, a UK-based diabetes home-testing provider, who graduated from our NHS Market Access Accelerator programme in 2022 have partnered with Medway NHS Foundation Trust to transform local gestational diabetes screening, by offering world-first home oral glucose tolerance testing (OGTT) technology to all at-risk women.
The collaboration involves the full implementation of GTT@home, the world’s first commercially available home use oral glucose tolerance test (OGTT) and the only alternative to traditional clinic-based testing.
GDM currently impacts up to 20% of UK pregnancies, with background risk factors including body mass index, age and ethnicity of the expectant mother. Undiagnosed or untreated, GDM can lead to complications during pregnancy including premature birth, preeclampsia and increased growth of the baby.
James Jackson, inventor of GTT@home and Chief Executive & Founder of Digostics, said:
“We are thrilled to work with Medway NHS Foundation Trust to offer home gestational diabetes screening to all at-risk women under their care.
Prior trials, together with multilingual provision for non-English speakers, gives us a high level of confidence that we can reach and screen key patient groups through GTT@home.
Because the test device analyses both blood samples immediately, the technology also eliminates the risk of sample degradation that can occur between sampling and laboratory analysis with clinic-based testing, leading to missed cases of GDM.”
More information can be found here.
Picture: Medway NHS Foundation Trust